153 completed. 153 Phase 2, 30 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 153 | Completed 153 |
| Phase 1 | 30 | Completed 30 |
| Phase 3 | 4 | Completed 4 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) Pub2Post - Prostate Cancer (Adenocarcinoma), Bladder Cancer | Phase 2 | Completed | University of Southern California | 120 | 2025-01-16 | 2026-05-06 |
| Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer Nivolumab, Visugromab (CTL-002), Placebo - Bladder Cancer, Adult Solid Tumor | Phase 2 | Completed | CatalYm GmbH | 31 | 2023-09-06 | 2026-08-19 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Brigimadlin - Pancreatic Neoplasms, Solid Tumors | Phase 2 | Completed | Boehringer Ingelheim | 99 | 2022-12-13 | 2026-10-14 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| Bladder Cancer and ExeRcise Training During IntraVesical ThErapy High-Intensity Interval Training - Bladder Cancer | Phase 2 | Completed | University of Alberta | 25 | 2021-12-09 | 2024-09-19 |
| Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma Pembrolizumab, Cryoablation, Avelumab - Metastatic Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Massachusetts General Hospital | 9 | 2021-06-04 | 2026-01-22 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention Tranexamic acid - Urologic Diseases, Prostate Cancer | Phase 1 / Phase 2 | Completed | Fraser Health | 14 | 2021-03-01 | 2021-11-05 |
| Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer Toripalimab, Gemcitabine - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Henan Cancer Hospital | 50 | 2021-01-04 | 2026-01-02 |
| Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors CPX-POM - Bladder Cancer | Phase 2 | Completed | CicloMed LLC | 12 | 2020-11-25 | 2024-06-18 |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Pemigatinib - Bladder Cancer, NMIBC | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2020-10-02 | 2025-10-03 |
| the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) - Bladder Cancer, Renal Carcinoma | Phase 2 | Completed | Dragonboat Biopharmaceutical Company Limited | 27 | 2020-09-11 | 2026-07-06 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies APR-246 (eprenetapopt) + Pembrolizumab - Bladder Cancer, Gastric Cancer | Phase 1 / Phase 2 | Completed | Aprea Therapeutics | 40 | 2020-06-25 | 2025-05-13 |
| Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) Fosfomycin Tromethamine 3G Sachet, Amikacin - Urinary Tract Infections, Bladder Cancer | Phase 2 | Completed | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 75 | 2020-01-01 | 2023-04-04 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane - Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | NGM Biopharmaceuticals, Inc | 89 | 2019-10-16 | 2025-05-29 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) IPI-549 (eganelisib), Nivolumab, Placebos - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 49 | 2019-09-25 | 2022-11-25 |
| Treatment of Recurrent Bladder Cancer With Dendritic Cells Dendritic cells, Standard treatment according to the Clinical protocols - Bladder Cancer | Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 17 | 2019-07-01 | 2021-01-22 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
Showing 20 of 153. Sign in to see all of them.
Urinary Bladder Neoplasms (153) · Carcinoma, Transitional Cell (23) · Urethral Neoplasms (22) · Prostatic Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (11) · Head and Neck Neoplasms (11) · Lung Neoplasms (11) · Ovarian Neoplasms (11) · Pancreatic Neoplasms (11) · Kidney Neoplasms (10) · Non-Muscle Invasive Bladder Neoplasms (10) · Stomach Neoplasms (10) · Esophageal Neoplasms (9) · Breast Neoplasms (8) · Uterine Cervical Neoplasms (8)
Female Urogenital Diseases (153) · Female Urogenital Diseases and Pregnancy Complications (153) · Male Urogenital Diseases (153) · Neoplasms by Site (153) · Urogenital Diseases (153) · Urinary Bladder Diseases (151) · Urogenital Neoplasms (151) · Urologic Diseases (150) · Urologic Neoplasms (148) · Neoplasms (147) · Neoplasms by Histologic Type (52) · Neoplasms, Glandular and Epithelial (49) · Carcinoma (48) · Endocrine Gland Neoplasms (22) · Endocrine System Diseases (22)
Gemcitabine (42) · Cisplatin (30) · Paclitaxel (14) · Carboplatin (12) · Docetaxel (9) · pembrolizumab (9) · Radiotherapy (7) · BCG Vaccine (6) · Doxorubicin (6) · Filgrastim (6) · Methotrexate (6) · Sunitinib (6) · Cystectomy (5) · Fluorouracil (5) · Ifosfamide (5)
Memorial Sloan Kettering Cancer Center (14) · SWOG Cancer Research Network (6) · Eastern Cooperative Oncology Group (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Radiation Therapy Oncology Group (4) · Cardiff University (3) · Dana-Farber Cancer Institute (3) · Hoffmann-La Roche (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · Seagen Inc. (3) · University Health Network, Toronto (3) · University of Chicago (3) · University of Michigan Rogel Cancer Center (3) · AstraZeneca (2)
United States (107) · Canada (18) · United Kingdom (16) · France (14) · Italy (14) · Spain (14) · Netherlands (9) · Belgium (8) · Germany (7) · Denmark (6) · South Korea (6) · Australia (4) · Israel (4) · Poland (4) · South Africa (4)
Dean F. Bajorin, MD (4) · Dean Bajorin, MD (3) · Robert Dreicer, MD, FACP (3) · Walter M. Stadler, MD, FACP (3) · Andrea Necchi, MD (2) · Colin P. Dinney, MD (2) · Dr. Sandy Srinivas (2) · Johann de Bono, Professor (2) · Toni Choueiri, MD (2) · Aldo V. Bono, MD (1) · Alexander V Prokharau, Dr (1) · Ali Abdalvand, MD (1) · Alon Weizer, M.D. (1)
PMID 25366678, PMID 29489427, PMID 37496366, PMID 41044356, PMID 41074972, PMID 10519404, PMID 12448661, PMID 12767086, PMID 12913696, PMID 15812833, PMID 15911238, PMID 16389183, PMID 16983508, PMID 17545536, PMID 18459175, PMID 18501081, PMID 18639470, PMID 19100600, PMID 19269798, PMID 19371909, PMID 19636012, PMID 19786668, PMID 20089114, PMID 21074799, PMID 21156335, PMID 21205754, PMID 21422406, PMID 21566413, PMID 21831711, PMID 22012004, PMID 22162575, PMID 22819172, PMID 22923433, PMID 22998907, PMID 23329066, PMID 23551593, PMID 23706253, PMID 23823157, PMID 24802654, PMID 24821883, PMID 26343003, PMID 26582660, PMID 26873642, PMID 26952546, PMID 27939400, PMID 28155045, PMID 28552987, PMID 28950298, PMID 29273410, PMID 29320312
U10CA032102 (5), 2014 (2), 2015 (2), 2017 (2), 2016 (1), 2023 (1), K23CA160664 (1), P30CA006516 (1), P30CA016086 (1), P30CA043703 (1), P30CA138292 (1), U10CA031946 (1), U10CA180888 (1)